Introduction
It is the usual practice at our centre to ensure that the benefits of visiting the annual North American Cystic Fibrosis Conference (NACFC) are not just confined to the members of the multidisciplinary team who attend the meeting but through formal feedback via in-house meetings and bulletins, also apply to the remainder of our staff, the patients and their families and carers. This year, the feedback of our own highlights has been given a wider audience through a presentation at the annual Royal Society of Medicine Cystic Fibrosis (CF) Meeting and this accompanying supplemental article and we welcome these opportunities.
The 2009 NACFC was held in Minneapolis and, despite this year's economic crisis, an impressive 3560 delegates attended the meeting. Over the three days of the conference there were roundtable and other discussion group meetings, fellows' sessions, physician grand rounds, 622 poster abstracts, 31 workshop sessions, 20 major symposia and three plenary sessions. The three plenary sessions from the conference are accessible free via the US CF Foundation website (http://www.cff. org/research/NACFC). This article from the five members of the Manchester Adult Multidisciplinary CF Team (MDT) who attended the 2009 conference (two consultant physicians, a clinical fellow, a pharmacist and a specialist dietician) captures some of their highlights from the meeting.
Emerging therapies
The NACFC presents an important opportunity to gain an update on the progress of the many exciting potential new therapeutic agents for the treatment of CF currently under investigation.
The initial results of the US phase II study of nebulized liposomal amikacin (Arikace TM ) were presented. 1 A 560 mg dose once daily delivered by an E-flow nebulizer for 28 days with follow-up for a further 28 days off treatment lead to a forced expiratory volume in 1 second (FEV 1 ) improvement of 9.6% at 56 days. Intriguingly, the improvement in FEV 1 seems to be sustained in the follow-up period off treatment, to a much greater extent than for the other nebulized antibiotics, such as Tobramycin Solution for Inhalation (TSI) and Aztreonam Lysine for Inhalation (AZLI). Further pooled data analysis of both the US and the recent European phase II studies is ongoing.
Three phase III studies of AZLI have been completed. It was announced that AZLI has just been granted conditional authorization for marketing in Europe and should be available in early 2010 for patients with CF aged >18 years for suppression of chronic P. aeruginosa. Full approval will be dependent upon the completion of a head-to-head non-inferiority trial in comparison with TSI with FEV 1 as the primary endpoint. Other ongoing studies include a placebo-controlled trial of AZLI for patients with milder lung disease (FEV 1 >75% predicted) and the AZLI Expanded Access Program allowing open label use for patients with FEV 1 <50% predicted which has over 500 patients already enrolled.
Dr Di Bilton presented the results of the European phase III study of inhaled mannitol (Bronchitol) 400 mg b.i.d. or placebo b.i.d. in 295 CF patients for 26 weeks. 2 There was a high withdrawal rate of 33.2% in the study. There was no statistically significant difference in the primary endpoint of the study, change in FEV 1 at 26 weeks, with an intention-to-treat analysis. A further analysis for those patients who took active treatment or placebo did show a 122 mL improvement in FEV 1 at 26 weeks with mannitol (p<0.001). The results of the further 26-week open label follow-up study are still awaited, and a further US phase III study is underway.
Drugs that may act as CFTR potentiators offer possible exciting novel treatments for CF. VX-770 is an oral drug that acts on malfunctioning CFTR at the cell surface creating a more effective opening of the CFTR chloride channel. The investigators reported that in a phase II study involving 39 patients with the class 3 G551D mutation (that accounts for approximately 2% of CF mutations), VX-770 was generally well-tolerated and 80% of patients receiving the higher dose of 250 mg twice daily for 28 days demonstrated improvements in FEV 1 of >5%, with 57% demonstrating an improvement of >10%. 3 A 12-month open label phase III study of Liprotamase, a non-porcine pancreatic replacement therapy, enrolled 215 patients. 4 The patients took an average of 5.4 capsules per day. There were minor elevations in liver enzyme levels noted in some patients. Sixty-nine (32.1%) patients withdrew due to adverse events, of which 37 (17.3%) were reported as gastrointestinal complaints or pulmonary exacerbations.
Many of the potential emerging therapies receive support through the CF Foundation's Drug Development Pipeline and further updates on the progress of these products is available through the through the CFF website (http://www.cff.org/res earch/DrugDevelopmentPipeline).
Azithromycin
The initial results of a large North American multicentre 24-week study of 3× weekly azithromycin (250 mg if weight 18-35.9 kg, 500 mg if weight >36 kg) for patients without chronic P. aeruginosa infection were presented. A total of 260 patients were enrolled in the study. There was no difference in the primary outcome measure of the study, change in %predicted FEV 1 between the groups. However, each group had a mean baseline FEV 1 of 98-99% predicted at the commencement of treatment, highlighting both how improvements in CF care are resulting in remarkable achievements in preserving lung function, as well as exemplifying the dilemma this success now presents for clinical studies that traditionally have used FEV 1 change as the primary endpoint and the clear need for new robust surrogate markers of lung disease to evaluate new therapies. The use of azithromycin did lead to a 0.34 improvement in body mass index (p<0.004), a 51% reduction in exacerbations (p=0.003) and a 26% reduction in rescue oral antibiotic use (p<0.001). While there was no difference in adverse events, study withdrawals or emergence of P. aeruginosa between the groups, there were greater rates of macrolide-resistant Staphylococcus aureus and macrolide-resistant Haemophilus influenzae in the treatment group (p<0.05). The findings of the subsequent 24-week open label follow-up are still awaited.
Infection control
The preliminary results of the US Early Pseudomonas Infection Control (EPIC) Study were discussed. A total of 304 children were randomized to one of two different anti-P. aeruginosa strategies: (1) regular quarterly cycled therapy; and (2) culture-based need for therapy, with patients in each treatment strategy receiving nebulized TSI 300 mg b.i.d. for 28 days, and either: (a) oral ciprofloxacin; or (b) placebo b.i.d. for 14 days. While the proportion of patients in the culture-based treatment arm had greater occurrence rates of P. aeruginosa positive samples during the study, eradication was usually successfully achieved such that at 18 months the prevalence rates of P. aeruginosa infection were <18% for both the cycled therapy and culture-based treatment groups. There were no differences in change in mean FEV 1 (p=0.51), mean weight (p=0.55) or time to pulmonary exacerbation (p=0.60) between the groups; however, patients in the cycled therapy groups received significantly more treatment than the culture-based treatment groups. Therefore, there was no additional benefit for a prophylactic regimen over a microbiological-based treatment intervention. The combination of ciprofloxacin with TSI was more effective at initial eradication of P. aeruginosa (p=0.03); however, those patients who had initially failed to eradicate P. aeruginosa received a further month of TSI and this lead to a similar overall success rate for eradication with either regimen. It should, however, be noted that the majority of respiratory samples received from patients were oropharyngeal swabs than sputum specimens (<6%). The CFF is planning to hold a consensus meeting to review the data from the study and provide recommendations based on the findings.
Two abstracts contributed to the debate concerning eradication of early P. aeruginosa infection, both by reporting their experiences of successful eradication of mucoid P. aeruginosa in several patients at their centres 5, 6 and, therefore, challenging the assumption that a change to a mucoid phenotype in P. aeruginosa signals the conversion from acute to chronic infection when eradication is no longer possible.
The prevention of P. aeruginosa infection also necessitates effective infection control measures against cross-infection. The Liverpool Paediatric CF Team presented data on their success of controlling the spread of the LES strain of Pseudomonas aeruginosa at their centre. The number of patients at their centre infected with this strain has fallen from 47 patients in 2003 to nine patients in 2009, as further spread has been arrested and the majority of children previously infected with LES have now moved on to adult care. 7 There were also several reminders of the importance of infection control and microbiological surveillance for cross-infection with other organisms. There has been a new outbreak of Burkholderia cenocepacia ET12 cross-infection at the Toronto Adult CF Center, with 4 out 5 of the new cases leading to early deaths within 37 to 104 days postacquisition. 8 An update of clinical outcome for patients infected with a single clone of Achromobacter xylosoxidans at the Cincinnati CF Center suggested that infection with the clonal strain was associated with a much greater rate of mean annual FEV 1 decline (10.8% per year) than with nonclonal strains (3.8% per year) of A. xylosoxidans (p=0.0036). 9 The latest report of the CFF registry gives a prevalence of 22.6% for Methicillinresistant Staphylococcus aureus (MRSA) in 2008. Further analysis of the CFF registry data suggests MRSA infection is associated with an increased mortality. 10 The hazard of death, adjusted for various confounders, associated with MRSA infection was 1.28, with a median survival of 33.9 years for those with MRSA infection compared with 41.4 years for those without MRSA. Furthermore, patients who had been infected with but cleared MRSA had a similar hazard ratio to those who never had MRSA.
Quality improvement/PORT CF
Quality improvement has been a major theme of the past few NACFCs. Initiatives in the UK to improve the quality of delivery of clinical care have included peer review of centres by the Cystic Fibrosis Trust. The Cystic Fibrosis Trust has recently successfully implemented an anglicised version of PORT CF as the new national database for UK CF centres. The immense potential for PORT CF as a tool for quality improvement was highlighted by an abstract comparing treatment differences and clinical outcome measures at Swedish and US CF centres. 11 The authors found lower use of gastric acid blockers, TSI, DNAase and inhaled steroids in the Swedish patients, but greater reported use of exercise, than in the US. Both countries, however, had similar outcomes in nutritional status and lung function. The successful introduction of PORT CF in the UK will allow CF teams to compare their individual clinic's data not just with other UK centres but also internationally. As more data are accrued, information on longitudinal trends will become possible for UK centres too. The authors of one abstract speculated that the slope of change in lung function may better reflect the impact of care within a site than single year or average of several years' data. 12
Vitamin D
In one symposium, the importance of vitamin D supplementation was emphasized, both for bone health and its emerging potential important roles in the regulation of other bodily systems in CF, including insulin secretion and sensitivity, muscle strength, innate immunity and lung function. One speaker called for a revision of the vitamin D supplementation guidelines with a focus more on prevention rather then treatment of vitamin D insufficiency, and a much higher recommended daily dose of 1000-2000 IU/day for all CF patients, with a further increase to 2000-4000 IU/day during winter.
intolerance were emphasized. It is clear that CFRD is associated with increased morbidity and mortality. The North American Consensus Committee reviewed the literature in September 2009 and presented the updated guidelines at the NACFC.
The Cystic Fibrosis Foundation Patient Registry has shown that the diagnosis of glucose intolerance is becoming more prevalent and in 2007 20.6% had a diagnosis of impaired glucose tolerance (IGT) or CFRD. An insidious decline in lung function and BMI can occur over 2-6 years before the diagnosis of CFRD. 13 Patients with CFRD have a higher mortality rate than people without diabetes. However, new data from Antoinette Moran's group are encouraging. This demonstrates that the mortality rate associated with CFRD has steadily fallen over the last 10 years at their centre. They propose this is due to early detection and aggressive treatment. 14
Diagnosis of CFRD: diagnostic criteria
The new criteria for the diagnosis of CFRD are shown in Table 1 . It is now possible to diagnose CFRD in two ways: on the oral glucose tolerance test (OGTT) and now an elevated HbA1c.
The OGTT is the gold standard test for diagnosing CFRD. The glucose tolerance categories have been modified ( Table 2 ). The distinction between CFRD with (FH+) or without fasting (FH-) hyper-glycaemia has been removed. The rationale is that the total duration of diabetes contributes to the cumulative risk of microvascular complications. In addition, CFRD FH-and CFRD FH+ both benefit from insulin therapy. A new category of indeterminate glucose tolerance (INDET) has been added which reflects the future risk of developing diabetes in patients who have abnormal glucose handling during the OGTT even if the results at 0 and 2 hours are normal.
HbA1c is often normal in CF regardless of the degree of hyperglycaemia and only 16% of patients have a raised HbA1C at the time of diagnosis. 15 However, in line with the new ADA criteria, if the HbA1c is >6.5% it is diagnostic of CFRD. However, it is important to note that an HbA1c <6.5% does not exclude a diagnosis of CFRD.
Different centres have historically defined the onset of diabetes at different points, e.g. the first abnormal OGTT or the start of therapy. The Consensus committee has defined the date of onset of CFRD to be the date when a patient first meets diagnostic criteria for diabetes, even if hyperglycemia subsequently abates. Defining this point allows comparison between studies.
For women not known to have diabetes, an OGTT should be done when planning to become pregnant or immediately upon confirmation of pregnancy to rule-out pre-existing CFRD if an OGTT has not been done within 6 months. A 2-h fasting 75 gram OGTT should be performed at 12-16 weeks and again at 24-26 weeks. The glucose threshold values for the diagnosis are in Table 3 . The new standards are based on the HAPO study. 16 The OGTT, performed when the patient is clinically stable, remains the test of choice for routine screening for CFRD. The results of the OGTT correlate with the clinical trials reporting increased morbidity in patients with CFRD and the response to treatment. The OGTT should be performed annually. The Consensus will recommend that screening begins at the age of 10 years, however, at the NACFC Dr Larson Ode raised the question Table 3 Diagnosis of gestational diabetes whether this should be lowered to 6 years. Their study demonstrated that children with abnormal glucose tolerance were at high risk for progression to early onset frank diabetes. 17 The Consensus Committee decided that home glucose monitoring devices (including CGM) are not sufficiently accurate to diagnose diabetes. The CGM has been validated for use in children and adolescents with CF. 18 If clinical suspicion is high, despite a normal or borderline OGTT result, CGM can help refine the diagnosis and the need for treatment.
The changing clinical aspects of CF
There was a reminder throughout the conference of how the advances in care are resulting in many changes in clinical outcomes and leading to new issues in the management of CF.
Traditionally the % predicted FEV 1 has been used as one of the key factors in considering the timing for referral of a patients for transplantation, with patients with a %FEV 1 of <30% having a mean mortality of greater than 50% within 2 years. 19 The Royal Brompton Hospital Adult CF Team presented their data of survival for patients with a FEV 1 of <30% predicted over the past two decades. Although there was a median survival of 2.1 years for 207 patients between 1990-1996, the median survival had improved to 5.4 years for the 188 patients with a FEV 1 of <30% predicted from 1997 to 2007 (p<0.0001). 20 The microbiology of CF was previously thought to be limited to a relatively select number of bacterial pathogens. However, it is becoming clear that the microbiological flora of the CF lung is far more diverse then previously thought and one of the last workshops of the conference was devoted to the emerging work on microbiological diversity and ecology in CF. Whether all the organisms present in the lung are pathogenic remains to be resolved. Gaining further understanding of the organisms present and their potential role in CF lung disease may in due course allow further improvements in the treatment of CF lung disease.
Summary
The 2009 meeting brought us exciting news on the progress of emerging treatments, updates on the continual evolution of clinical issues and of tools, such as PORT CF, for assessing and helping further improve the quality of clinical care for patients with CF worldwide. We look forward to the next NACFC in Baltimore, on 21-23 October 2010!
